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Poster Session-II 137evident in lymphopenic patients, suggesting that lymphopenia-
driven proliferation and apoptosis skew Treg reconstitution. This
homeostatic process does not affect the survival of other CD4 T
cell subsets, resulting in a relative deficiency of Treg post-HSCT.
Our findings provide important information for developing strate-
gies to modulate Treg and promote immune tolerance after
HSCT.382
CELLULAR IMMUNE RECONSTITUTION AND ITS IMPACT ON CLINICAL
OUTCOME IN CHILDREN WITH THALASSEMIA MAJOR UNDERGOING A
MATCHED RELATED ALLOGENEIC BONE MARROW TRANSPLANT (BMT)
Rajasekar, R., Mathews, V., Lakshmi, K.M., George, B.,
Viswabandya, A., Chandy, M., Srivastava, A. Christian Medical College,
Vellore, Tamil Nadu, India
We have prospectively analyzed cellular immune reconstitution
(IR) in pediatric patients with ß thalassemia major who underwent
myeloablative HLA matched related allogeneic BMT at our centre.
A total of 63 such consecutive patients were included in the study.
Samples from bone marrow graft and post-transplant peripheral
blood samples from recipients (day 15, 28, 45 and 2, 3, 6, 9 and 12
months) were assessed for stem cells, lymphocytes and dendritic
cell subsets. The median age of the cohort was 7 years (range: 2–
14) and there were 37 (59%) males. All patients received myeloabla-
tive conditioning regimen. Bone marrow was the graft source in
61(unprimed in 37; G-CSF primedmarrow in 24) while two patients
received PBSC. Cyclosporine and short course methotrexate was
used as GVHD prophylaxis. A CD34 cell dose above the median
value of 7.3  106/Kg had a lower incidence of bacterial (P 5
0.003) and fungal (P5 0.003) infections in the post-transplant period
and was not associated with an increased risk of GVHD.Themedian
time to engraftment was not different between these groups (17 vs.
16 days, P 5 0.531). Among cases that did develop grade II-IV
GVHD the absolute CD8 (116 vs.52 cells/ml, P5 0.012), both naı¨ve
(74 vs. 9 cells/ml, P 5 0.005) and memory counts (44 vs.21 cells/ml,
P5 0.010) were significantly higher on day 15. Only one of eight pa-
tients who eventually developed acute GVHD had evidence of acute
GVHD at this time point. Fifteen patients (24%) rejected their graft
(7 primary and 8 secondary). The day 28 NK cell count was signifi-
cantly associated with secondary graft rejection, EFS and OS when
analyzed as continuous variable in univariate analysis (P 5 0.044,
0.013 and 0.034 respectively). On a multivariate analysis, patients
with #142 NK cells/ml (median value) on day 28 had significantly
higher rejection (HR 5 11.1, P 5 0.038) and lower EFS (HR 5
16.3, P 5 0.034). Table 1 compares the characteristics of cases
with a day 28 NK cell count # the median value and those above
it. These data suggest that the stem cell dose along with patterns
of cellular IR have a significant impact on clinical outcomes such
as infection, rejection and EFS.Table 1. Comparison of low and high day 28 NK cell count
patient groups
Day 28 NK
cell count
[n (%) / median (range)]CharacteristicsLow
(# 142/ml)
n526High
(142/ml.)
n526 P-valueAge (years) 7 (2 – 14) 8 (2 – 13) 0.904
Males 15 (58) 16 (62) 1.000
Sex mismatch transplant 10 (39) 9 (35) 1.000
Lucarelli Class III 14 (54) 11 (42) 0.579
TNC (10E8/Kg) 4.2 (1.7 – 10) 4.6 (1.7 – 22.7) 0.442
ANC .500 /mm3 17 (11 – 23) 16 (13 – 20) 0.358
Acute GVHD (Grade II-IV) 3 (12) 4 (15) 1.000
Chronic GVHD 2 (9) 3 (13) 1.000
Secondary graft rejection 7 (35) 1 (4) 0.021
EFS at 3 years 64 6 10% 96 6 4% 0.006383
RAPID GENERATION OF ANTIGEN-SPECIFIC T CELLS FOR PRE-CLINICAL
AND CLINICAL APPLICATIONS USING A NOVEL MINI CELL BIOREACTOR
Brenner, L.1, Leen, A.M.1, Wilson, J.2, Heslop, H.E.1, Dotti, G.1,
Rooney, C.M.1, Vera, J.F.1 1Baylor College of Medicine, Houston, TX;
2Wilson Wolf Manufacturing, New Brighton, MN
The production of antigen-specific T cells for the reconstitution
of tumor or pathogen-specific immunity after HSCT is limited by
the time taken to produce large T cell numbers, while retaining
function and specificity. The requirements for expansion of anti-
gen-driven cytotoxic T lymphocytes (CTLs) are rigorous, and in
some cases only possible in 2 cm2 wells. Conventional cell growth
is limited by gas exchange, nutrients and waste build-up. Bioreac-
tors developed to solve these problems tend to be complex and ex-
pensive and not always conducive to antigen-specific T cell
growth. We have now explored the use of a new static mini Cell
Bioreactor (CBR); essentially a flask with a gas permeable mem-
brane base. The O2/CO2 exchange from the base allows large
heights of media above the cells reducing nutrient limitations,
waste build-up, and manipulation. We tested two different sizes
of CBR, 10 cm2 and 100 cm2 that hold a maximum of 40mL
and 2000L of media, respectively. We were able to generate and
expand Epstein-Barr virus antigen-specific cytotoxic T lympho-
cytes (EBV-CTLs) from normal donors by coculturing antigen
presenting cells (APC) (1.4E105 x cm2) with established EBV
CTL (4.3E103 x cm2) at an optimized cell density and stimulator:
responder ratio (32:1). These culture conditions produced higher
cell yields in the CBR vs. conventional method (42.5 fold 614.8
vs 3.4 fold 61.2 within 7 days) without media change, and manip-
ulation restricted to cytokine addition every 3–4 days. A single
100cm2 bioreactor could produce up to 800E106 antigen-specific
T cells from a starting 10E106 PBMC, which would have re-
quired approximately 320 wells in 24 well plates under standard
culture conditions. The CD4:CD8 T cell ratio and phenotype
was similar to those expanded using the conventional method
(CD27 48% vs 52.4%, CD28 65.2% vs 62.2%, CD62L 53.15%
vs 54.5%, CD45RO 58.1% vs 55.7%, and CD45RA 51.1% vs
54.9%). Antigen specificity, as evaluated by tetramer analysis,
and IFN-g ELIspot and chromium release assays revealed no sig-
nificant differences. In summary, we have successfully utilized the
new mini Cell Bioreactor technology to induce optimal in vitro ex-
pansion of virus-specific CTLs with minimal handling. This new
cell culture technology can readily be extended it to others cells
products in order to facilitate the application of cell therapy ap-
proaches. This work was supported in part by a Production Assis-
tance for Cellular Therapies PACT (NO1HB37163–C001) from
NHLBI384
ABSOLUTE LYMPHOCYTE COUNT KINETICS MAY PREDICT THE CLINICAL
OUTCOME AFTER RELATED ALLOGENEIC PERIPHERAL BLOOD STEM
CELL TRANSPLANTATION WITH A BUSULFAN-BASED REDUCED-INTEN-
SITY CONDITIONING REGIMEN
Yakushijin, K., Fukuda, T., Saito, B., Kurosawa, S., Asakura, Y.,
Azuma, T., Kim, S.-W., Mori, S.-i., Tanosaki, R., Heike, Y.,
Takaue, Y. National Cancer Center Hospital, Tokyo, Japan
In autologous hematopoietic stem cell transplantation (HSCT),
early recovery of the absolute lymphocyte count (ALC/mm3) is
known to be associated with better overall survival (OS). Although
similar observations have been reported after myeloablative alloge-
neicHSCT, little is known in the setting of RIST. Previously, we ob-
served that donor T-cell chimerism at 1 month after busulfan-based
RIST may predict the clinical outcome (Saito et al., BBMT, 2008).
To further extend this analysis, we retrospectively reviewed themed-
ical records of 88 patients (median age, 54 y (29–68)) who underwent
busulfan-based RIST at our hospital between 2000 and 2007. The
conditioning regimen consisted of busulfan (oral 8 mg/kg or iv 6.4
mg/kg) and fludarabine (180 mg/m2, n 5 41) or cladribine (0.66
mg/kg, n 5 47), and one patient received 2Gy TBI. The diagnosis
included ML (n 5 37), AML/MDS (n 5 38), and other (n 5 13).
All patients received G-CSF-mobilized PBSCs from related donors
*C. Difficile infections were excluded.
138 Poster Session-II(HLAmatch, n5 72; mismatch, n5 16), which contained a mean of
4.0 106 CD341 cells/kg (0.9–10.9  106 cells/kg) and 3.4  108
CD31 cells/kg (1.1–9.0 108 CD31 cells/kg). GVHD prophylaxis
consisted of cyclosporine (n5 71) or tacrolimus (n5 17), with (n5
20) or without (n 5 68) MTX, and 24 patients received additional
ATG (5–10 mg/kg, Fresenius). The median values of ALC on days
0, 7, 14, 21, and 28 were, respectively, 68 (0–1460), 229 (0–1320),
675 (0–3185), 601 (0–3357), and 662 (0–2016). The median fol-
low-up was 2 years (0.3–6.9). In the 36 patients whose ALC on day
0 was below 100, the proportion of patients who achieved complete
donor T-cell chimerism (.90%) on day 28 was significantly higher
than that of patients with ALC.100 (65% vs. 33%, p5 0.003). Pa-
tients whose ALC on day 0 was below 100 tended to show better OS
than those with a value above 100 (69% vs. 63% at 2 y, p 5 0.19).
Furthermore, 50 patients whose ALC on day 28 was above 600
tended to show higher probabilities of grade II-IV aGVHD (54%
vs. 34%, p 5 0.051) and cGVHD (52% vs. 37%, p 5 0.12) than
the remaining 38 patients. However, the rate of positive CMV anti-
genemia (60% vs. 50%), relapse rate (42% vs. 37%), andOS (67% vs.
68%) at 2 y were not significantly different according to ALC on day
28. In conclusion, lowALC on day 0may become a surrogatemarker
for effective host immune suppression resulting in higher donor T-
cell chimerism after busulfan-based RIST, and early recovery of
ALC on day 28 after RIST may predict GVHD, but not relapse or
OS.385
VIRAL INFECTIONS ARE THE GREATEST CAUSE OF INFECTIOUS MORTAL-
ITY AFTER CORD BLOOD (CB) TRANSPLANTATION (CBT) BUT THE MOR-
TALITY RISK IS LIMITED TO THE FIRST 4 MONTHS
Sauter, C., Abboud, M., Hawke, R.M., Heller, G., Scaradavou, A.,
Barker, J.N. Memorial Sloan-Kettering Cancer Center, New York, NY
As CBT is associated with prolonged neutropenia the infection
risk in the pre-engraftment period has received the most emphasis.
However, aggressive antimicrobial prophylaxis can be effective in
decreasing the lethality of bacterial and fungal infections whereas
viral infections remain challenging. We reviewed the incidence
of serious opportunistic infections (OI) in CBT recipients with
the hypothesis that viral infections pose the biggest infectious le-
thality risk. 52 patients [median 38 years (range 3–66); 12 AML,
12 ALL, 28 lymphoma] received myeloablative (MA, n 5 36) or
non-myeloablative (NMA, n 5 16) conditioning with cyclospor-
ine-A/ mycophenolate mofetil and GCSF. Double unit grafts (4-
6/6 HLA-A,B antigen, DRB1 allele matched to the patient) were
used to enhance engraftment. Serious OI were defined as severe
(required IV therapy/ admission), life-threatening, or fatal (caused
or contributed to death). The cumulative incidence (CI) of sus-
tained donor engraftment was 94% (95%CI:88–100) with the en-
grafting unit [1 6/6, 24 5/6, 23 4/6] having a median infused TNC
dose of 2.2  107/kg (range 1.3–5.3). The median neutrophil
recovery was 25 days (range 13–43) in MA and 11 days (range
7–36) in NMA recipients. The CI of grade II-IV acute graft-
vs-host disease (GVHD) at day 100 was 40% (95%CI:27–53)
and 6 patients have chronic GVHD to date. The day 180 trans-
plant-related mortality was 24% (95%CI:13–35) and the 1 year
overall survival is 64% (95%CI:52–80). The median CD41
count/microL (359–1570) at days 60, 120, 180 and 1 year were
188, 272, 375 and 570, respectively. The median phytohemagglu-
tinin (PHA) response (normal .92k) at these time points were
64k, 89k, 96k, and 140k, respectively. OIs by time-period are sum-
marized below. ‘‘Pneumonias’’ responded to combined anti-bacte-
rial/fungal therapy and the exact etiology was unknown. Viral
infections accounted for the greatest infectious mortality. In
contrast to bacterial/ fungal infections that diminished after day
30 viral infections continued to be a major problem in the post-
engraftment period. However, subsequently their incidence
decreased possibly related to immune recovery as suggested by
a median CD41 count .250/microL and PHA response .95%
the lower limit of normal by day 1120. In summary, the greatest
risk for infection-related death is due to viral infections. Improved
anti-viral agents and augmentation of anti-viral immunity should
be a major priority in CBT.Opportunistic Infections by Time Period
Time *Bacterial Fungal Viral Pneumonia TotalAdmit-30
(n552)19 (2 lethal) 9 (0 lethal) 16 (2 lethal)
(2 CMV;
9 HHV6;
4 BK; 1 Adeno)3 (0 lethal) 47 (4 lethal)131–60
(n548)11 (0 lethal) 1 (0 lethal) 15 (2 lethal)
(10 CMV;
1 HHV6; 3 BK;
1 Adeno)0 27 (2 lethal)161–120
(n541)4 (0 lethal) 1 (0 lethal) 6 (1 lethal)
(2 CMV;
1 Adeno; 1 RSV;
1 Influenza;
1 H. Zoster)1 (0 lethal) 12 (1 lethal)1121–180
(n533)3 (0 lethal) 0 4 (0 lethal)
(1 CMV;
1 EBV; 1 RSV;
1 Influenza)0 7 (0 lethal)1180–1 yr
(n521)1 (0 lethal) 0 3 (0 lethal)
(1 CMV; 2 EBV)0 4 (0 lethal)Total 38 (2 lethal) 11 (0 lethal) 44 (5 lethal) 4 (0 lethal) 97 (7 lethal)386
CHIMERISM DETECTION IN HEMATOPOIETIC CELL TRANSPLANT RECIP-
IENTS BY REAL-TIME QUANTITATIVE PCR (Q-PCR) VS. SHORT TANDEM
REPEAT (STR) ANALYSIS
Senitzer, D.1, Zhou, Y.1, Gaidulis, L.1, Lazaruk, K.2 1City of Hope Na-
tional Medical Center, Duarte, CA; 2Celera, San Francisco, CA
STR is now being routinely used for chimerismdetection inHCT.
However, the sensitivity (\5%), multiplex PCR competition, and
stutter band artifacts complicate quantitative analysis.We have eval-
uated a real-time quantitative PCR (Q-PCR)method for chimerism
detection, and compared it with STR analyses. The ABI
AmpFLSTR Identifiler Kit with 15 allelic markers was used for
the STR chimerism study. Q-PCR procedure includes screening
with 34 polymorphic markers to identify informative loci, followed
by quantitation of the informative loci. The percentage of recipient
chimerism is calculated based on the cycle threshold (Ct) value. To
determine the accuracy of the Q-PCR method, fifty one peripheral
blood, bone marrow, and cell subset samples from related and unre-
lated transplant cases were compared. The difference of the% recip-
ient between Q-PCR and STR is listed in Table 1. To summarize,
8% of the Q-PCR data are exactly the same as the STR data; 86%
have less than a 5% difference and 6% have less than a 10% differ-
ence. The sensitivity of the Q-PCR assay can reach 0.1% based on
our serial dilution study. The specificity of the Q-PCR is 100%
based on a 20 sample study. Both within run precision and between
run precision of the Q-PCR are less than 10%. The variant amplifi-
cation efficacy of each primer set in themultiplex STR contributes to
the lower accuracy. Q-PCR eliminates the multiplex feature, and
quantifies data with internal calibration. Q-PCR chimerism assay
gives a high dynamic detection range from less than 0.1% to
100%. This advantage can be very useful in early detection of re-
lapse. Ease of operation, and automated data analysis is a further ad-
vantage of Q-PCR, resulting in significant saving in labor costs . In
conclusion, Q-PCR is a simple, fast, sensitive, and accurate assay for
detection and quantitation of chimerism in HCT recipients.Table 1. Chimerism Analysis By Q-PCR vs. STR
% Difference Between
Q-PCR & STR ASHI Related Unrelated Total %0.0 2 0 2 4 8
0.1-5.0 11 11 22 44 86
5.1-10.0 1 1 1 3 6
Total 14 12 25 51 100
